MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx

New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.

Episode metadata supplied by the publisher feed · Published Jun 2, 2023

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx

0:00 12:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 12 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on June 2, 2023.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!